SAMM50 and sarcopenia: From a clinical perspective, the potential of ENSA, FAM43A, MDH2, NUBP1, SAMM50, and TM2D1 as biomarkers is promising, as they may be measurable in peripheral blood or muscle biopsy specimens to support early screening and individualized diagnosis of AS patients at risk of sarcopenia.